Phaseline

Targets › M3

M3: drug programs, companies and trials

3 programs from 2 companies in 5 trials: 5 Phase 2; Ophthalmology.

Open in Phaseline: the race on M3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Zhaoke (Guangzhou) Ophthalmology PharmaceuticalBRIMOCHOL PF eye drops
Combined alpha-2A adrenergic agonist and muscarinic M3 receptor agonist
ADRA2A, M3Phase 2Presbyopia–
BioTheraVisionBTV100 Low dose (1% Cevimeline Ophthalmic Solution)
M3 muscarinic receptor agonist
M3Phase 2Dry Eye–
Zhaoke (Guangzhou) Ophthalmology PharmaceuticalCARBACHOL PF eye drops
Muscarinic M3 receptor agonist (cholinergic miotic)
M3Phase 2Presbyopia–

Conditions

Dry Eye (3) Presbyopia (2)

Modalities

small molecule (1)

Companies

Zhaoke (Guangzhou) Ophthalmology Pharmaceutical (2) BioTheraVision (1)

Related targets

ADRA2A (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.